Pluristem Therapeutics, Inc. (PSTI) News

Pluristem Therapeutics, Inc. (PSTI): $1.29

0.03 (+2.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSTI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter PSTI News Items

PSTI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PSTI News From Around the Web

Below are the latest news stories about Pluristem Therapeutics Inc that investors may wish to consider to help them evaluate PSTI as an investment opportunity.

15 Worst Stock Picks of Cathie Wood

In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the champion of “disruptive innovation” at the stock market. […]

Yahoo | January 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 18, 2022

PSTI, BLRX and BBIG among pre-market gainers

Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%

Seeking Alpha | January 18, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 10, 2022

Pluristem jumps on collaboration with Tnuva to develop cultured cell-based food products

Pluristem Therapeutics (PSTI) and Tnuva Group, Israel’s largest food producer, announce the launch of an innovative collaboration to develop, manufacture and commercialize…

Seeking Alpha | January 10, 2022

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

Pluristem Therapeutics Inc (NASDAQ: PSTI ) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products. The collaboration started with the incorporation of a new company (NewCo) that will receive exclusive, global, royalty-bearing licensing rights to use Pluristem''s Full story available on Benzinga.com

Benzinga | January 10, 2022

Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com

Benzinga | January 10, 2022

Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Yaky Yanay, CEO and President, Pluristem Yaky Yanay, CEO and President, Pluristem Zami Aberman, Chairman, Pluristem Zami Aberman, Chairman, Pluristem Haim Gavrieli, Chairman, Tnuva Group Haim Gavrieli, Chairman, Tnuva Group Eyal Malis, CEO, Tnuva Group Eyal Malis, CEO, Tnuva Group Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and development (R&D), c

Yahoo | January 10, 2022

Dawson James Maintains a Buy Rating on Pluristem (PSTI)

Dawson James analyst Jason Kolbert maintained a Buy rating on Pluristem (PSTI – Research Report) on December 1 and set a price target of $9.00. The company's shares closed last Tuesday at $1.53. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $9.00 average price target.

Christine Brown on TipRanks | January 5, 2022

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Yahoo | December 28, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6095 seconds.